×

Entia Biosciences, Inc. Begins Clinical Study of Proprietary ErgoD2® Medical Food Product to Demonstrate Improved Health for the More Than 25 Million Chronic Kidney Disease Sufferers in the U.S.

PORTLAND, Ore., Dec. 21, 2015 (GLOBE NEWSWIRE) -- Entia Biosciences, Inc. (OTCQB:ERGO) Founder and Chief Science and Technology Officer, Dr. Marvin Hausman, has reported greater-than-expected initial enrollment in Entia’s Chronic Kidney Disease study. This milestone was achieved during his recent kickoff visit to the study’s test sites in Columbia (South America) and on the Caribbean island of Bonaire. The initial enrollees represent more than 25% of the quantity of study participants ultimately anticipated to enroll.

This significant number of patients is actively participating in the stabilization phase of the study.

Chronic Kidney Disease takes a significant toll on the health of more than 25 million individuals in the U.S. alone. Progression of the disease leads to dialysis, and eventually the need for a kidney transplant. The cost to the U.S. Healthcare system was reported as $42.5 billion in 2009 by the National Institutes of Health, and has been growing at a compound rate of +9.8% annually.

The product being tested is a specific proprietary blend of Entia’s patented ErgoD2® technology. Entia Biosciences is the first company to develop, produce and market consumer products with all-natural formulas for the amino acid Ergothioneine and enhanced vitamin D2. This novel medical food is a supplement to a patient’s existing prescribed regimen of care and is intended to improve iron levels, increase production of red blood cells and increase kidney filtration rates. If the study proves successful, Entia’s ErgoD2 product formulation for Chronic Kidney Disease will provide patients with the first all-natural, organic medical food product designed to improve the health and well-being of the patient, enhance the dietary management of the disease and potentially slow its progression.

Dr. Hausman has been consulting with Dr. Hector Rodriguez, Nephrologist at Cedars-Sinai Medical Center in Los Angeles. In an earlier pilot study of the beneficial effects of the ErgoD2 formulation, Dr. Rodriguez commented, “The results of this study provide a basis for the application of ErgoD2 medical food to potentially modify the course of Chronic Kidney Disease and the nearly inexorable loss of kidney function that dictates the need for dialysis or transplantation.”

The application of ErgoD2 is not limited to Chronic Kidney Disease; Entia believes that ErgoD2’s ability to improve iron homeostasis has the potential to mitigate many other conditions related to iron dysfunction. Entia plans to address several disease markets, all characterized by dysfunctional iron disorders, in which it believes its products may be of significant efficacy. These disorders, associated with oxidative stress and inflammation, include, but are not necessarily limited to, Anemia, Chronic Kidney Disease, Autism and various neurodegenerative diseases, such as Parkinson's and Multiple Sclerosis.

About Entia Biosciences, Inc.

Entia (OTCQB:ERGO) discovers, scientifically validates, develops and markets patented, pharmaceutical-grade organic compounds that include its revolutionary ErgoD2®. The Company is a leading authority on the clinical effects of oxidative stress, iron-related disorders and free radical reactions in mammals; it is bringing this expertise to the nutraceutical and medical foods markets. Entia also develops and markets health-related cosmeceuticals.

Entia Biosciences, Inc. is headquartered in Sherwood, Oregon, a Portland suburb.

Forward-Looking Statements

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the transaction described in this press release, and other risks identified in the filings by Entia Biosciences, Inc. with the Securities and Exchange Commission. Further information on risks faced by the Company and its shareholders are detailed in the Form 10-K for the year ended December 31, 2014 and in its subsequent Quarterly Reports on Form 10-Q. These filings are or will become available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. Entia does not undertake any obligation to publicly release the result of any revision to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.



Contact: Carl Johnson or Tim Timmins (844-599-9910)

Source:Entia Biosciences, Inc.